Advertisement
CGEN or GILD or SGMO
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGEN’s FA Score shows that 1 FA rating(s) are green whileGILD’s FA Score has 4 green FA rating(s), and SGMO’s FA Score reflects 0 green FA rating(s).
- CGEN’s FA Score: 1 green, 4 red.
- GILD’s FA Score: 4 green, 1 red.
- SGMO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGEN’s TA Score shows that 5 TA indicator(s) are bullish while GILD’s TA Score has 4 bullish TA indicator(s), and SGMO’s TA Score reflects 4 bullish TA indicator(s).
- CGEN’s TA Score: 5 bullish, 5 bearish.
- GILD’s TA Score: 4 bullish, 5 bearish.
- SGMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
CGEN (@Biotechnology) experienced а -5.17% price change this week, while GILD (@Pharmaceuticals: Major) price change was -0.49% , and SGMO (@Biotechnology) price fluctuated -5.38% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.02%. For the same industry, the average monthly price growth was +29.50%, and the average quarterly price growth was +16.11%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.05%. For the same industry, the average monthly price growth was +4.43%, and the average quarterly price growth was +8.27%.
Reported Earning Dates
CGEN is expected to report earnings on Jul 31, 2025.
GILD is expected to report earnings on Aug 05, 2025.
SGMO is expected to report earnings on Aug 12, 2025.
Industries' Descriptions
@Biotechnology (+11.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-2.05% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| CGEN | GILD | SGMO | |
| Capitalization | 152M | 90.8B | 112M |
| EBITDA | -14.79M | 10.5B | -72.14M |
| Gain YTD | 7.843 | 18.578 | -55.147 |
| P/E Ratio | 64.00 | 16.20 | N/A |
| Revenue | 27.6M | 27.1B | 63.8M |
| Total Cash | 104M | 7.26B | 25.2M |
| Total Debt | 2.77M | 25B | 24.9M |
CGEN | GILD | SGMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 42 | 20 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 17 Undervalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 16 | 100 | |
SMR RATING 1..100 | 95 | 29 | 100 | |
PRICE GROWTH RATING 1..100 | 46 | 16 | 65 | |
P/E GROWTH RATING 1..100 | 21 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 19 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (17) in the Biotechnology industry is somewhat better than the same rating for CGEN (77) and is somewhat better than the same rating for SGMO (79). This means that GILD's stock grew somewhat faster than CGEN’s and somewhat faster than SGMO’s over the last 12 months.
GILD's Profit vs Risk Rating (16) in the Biotechnology industry is significantly better than the same rating for CGEN (100) and is significantly better than the same rating for SGMO (100). This means that GILD's stock grew significantly faster than CGEN’s and significantly faster than SGMO’s over the last 12 months.
GILD's SMR Rating (29) in the Biotechnology industry is significantly better than the same rating for CGEN (95) and is significantly better than the same rating for SGMO (100). This means that GILD's stock grew significantly faster than CGEN’s and significantly faster than SGMO’s over the last 12 months.
GILD's Price Growth Rating (16) in the Biotechnology industry is in the same range as CGEN (46) and is somewhat better than the same rating for SGMO (65). This means that GILD's stock grew similarly to CGEN’s and somewhat faster than SGMO’s over the last 12 months.
CGEN's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for GILD (100) and is significantly better than the same rating for SGMO (100). This means that CGEN's stock grew significantly faster than GILD’s and significantly faster than SGMO’s over the last 12 months.
| CGEN | GILD | SGMO | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | N/A | 4 days ago 76% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 48% | 3 days ago 76% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 53% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 88% | 3 days ago 35% | 3 days ago 71% |
| TrendWeek ODDS (%) | 3 days ago 89% | 3 days ago 49% | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 79% | 3 days ago 60% | 3 days ago 78% |
| Advances ODDS (%) | 18 days ago 82% | 12 days ago 58% | 10 days ago 74% |
| Declines ODDS (%) | 8 days ago 89% | 10 days ago 51% | 8 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 80% | 3 days ago 44% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 68% | 3 days ago 58% | 3 days ago 90% |
Advertisement
CGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.
| Ticker / NAME | Correlation To CGEN | 1D Price Change % | ||
|---|---|---|---|---|
| CGEN | 100% | N/A | ||
| NURPF - CGEN | 46% Loosely correlated | N/A | ||
| BDTX - CGEN | 45% Loosely correlated | +0.43% | ||
| ASPHF - CGEN | 41% Loosely correlated | N/A | ||
| ROIV - CGEN | 41% Loosely correlated | +2.97% | ||
| ORMP - CGEN | 40% Loosely correlated | -0.46% | ||
More | ||||
GILD and
Correlation & Price change
A.I.dvisor indicates that over the last year, GILD has been loosely correlated with AMGN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To GILD | 1D Price Change % | ||
|---|---|---|---|---|
| GILD | 100% | N/A | ||
| AMGN - GILD | 46% Loosely correlated | -0.14% | ||
| BMY - GILD | 45% Loosely correlated | -0.83% | ||
| PFE - GILD | 43% Loosely correlated | -0.50% | ||
| ABBV - GILD | 41% Loosely correlated | +0.01% | ||
| JNJ - GILD | 40% Loosely correlated | -1.08% | ||
More | ||||
SGMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, SGMO has been loosely correlated with AXON. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SGMO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To SGMO | 1D Price Change % | ||
|---|---|---|---|---|
| SGMO | 100% | -6.84% | ||
| AXON - SGMO | 51% Loosely correlated | +0.85% | ||
| ARRY - SGMO | 48% Loosely correlated | -1.86% | ||
| BCRX - SGMO | 46% Loosely correlated | +1.41% | ||
| RPRX - SGMO | 45% Loosely correlated | -0.11% | ||
| AGEN - SGMO | 43% Loosely correlated | +7.05% | ||
More | ||||